Trial on the Safety and Efficacy of MLS-101 in Patients With Uncontrolled Hypertension

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 200 participants.

Also called NCT05001945

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 200 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05001945
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05001945. Randomized; quadruple masking; primary purpose treatment. Start 2021-07-01 (actual); primary completion 2022-09-07 (actual). Results posted on 2024-01-05.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Trial on the Safety and Efficacy of MLS-101 in Patients With Uncontrolled Hypertension
Acronym
Target-HTN
Condition
Hypertension, Renal
Intervention (Drug)
MLS-101 (Part I)
Intervention (Other)
Placebo (Part I)
Intervention (Other)
Placebo (Part II)
Intervention (Drug)
MLS-101 (Part II)
Lead sponsor
Mineralys Therapeutics Inc. (class: industry)

Record details

Record id
cardio:ct-nct05001945
Content hash
91e211e7fe6ab434994ae4b9d4177fe54434c310340c5ca4f9b8aa81db65da45